Image

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

Recruiting
6-75 years
All
Phase 3

Powered by AI

Overview

The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).

Eligibility

Inclusion Criteria:

  • Subject must be between 6 months and 75 years old
  • Subject has biochemically and genetically proven LAD II (SLC35C1-CDG)
  • Subject has a documented history of Lewis antigen deficiency
  • Subject has a history of recurrent infections, opportunistic infections or infections that did not respond well to standard of care treatment
  • Subject or parent (for subjects under legal age for consent) has provided written informed consent for this study. Additionally, written informed assent has been provided, as appropriate, for minors of older age, per local institutional review board (IRB)/ethics committee (EC) policy and requirements
  • Subject is willing and able to comply with the protocol
  • Women of childbearing potential (WOCBP) meeting the criteria below:
    1. Non-lactating and has a negative pregnancy test at screening -AND-
    2. Uses an acceptable double-barrier method of contraception as determined by the investigator or sub-investigator for the duration of the study and 30 days following the last dose of study drug.
  • Male subjects must agree to use an acceptable double-barrier method of contraception with their partner as determined by the investigator or sub-investigator for the duration of the study and 30 days following the last dose of study drug.

Exclusion Criteria:

  • Subject has severe anemia defined as hemoglobin \<8.0 g/dL (\<4.9 mmol/L)
  • Subject has impaired renal function as defined by an eGFR \<90 mL/min
  • Subject has a total absence of fucosylation on red blood cells and the presence of anti-H antigen
  • Subject has known or suspected intolerance or hypersensitivity to fucose or any ingredients of the investigational product
  • In the investigator's opinion, subject has a history of failure to respond to fucose at adequate dosing
  • In the investigator's opinion, subject is not able or not willing to comply with the study requirements.
  • Subject is pregnant

Study details
    Leukocyte Adhesion Deficiency

NCT05462587

AUG Therapeutics

14 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.